Shopping Cart is Empty..

$ 0

Ischemic Heart Disease Drugs Market by Disease (Angina Pectoris [Stable Angina, Unstable Angina, and Prinzmetals Angina], and Myocardial Infarction [STEMI and NSTEMI]) and by Drug Class (Anti-dyslipidemic Drugs, Calcium Channel Blockers, Beta-blockers, ACE Inhibitors, ARBs, Vasodilators, and Antithrombotic Agents) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Pharmaceuticals	LI 173689	Pages: NA	Formats*:
Oct 2017 \| 69 Views	Charts: NA	Tables: NA	Author(s): NA

Ischemic Heart Disease (IHD) is an abnormal condition of the heart that often occurs during excitement and exertion when the heart needs more blood supply. The condition occurs due to a blockage of the arteries that supply blood to the heart, which is the consequence of a buildup of plaque in the arteries. As a result of lack of sufficient blood supply, the patient may suffer from recurrent chest pain and discomfort leading to a condition called angina pectoris.

Prolonged blockage of the arteries results in lack of blood supply leading to the death of the heart tissues, which in turn causes a condition called myocardial infarction. The condition is usually asymptomatic and develops slowly. The common symptoms include chest pain and shortness of breath. A range of medications such as nitrates, statins, beta-blockers, and antiplatelet drugs, along with treatment options such as angioplasty and coronary artery bypass graft are available depending on the condition of the patient.

The growing population of individuals with IHD is the major factor that contributes towards the market growth. In addition, as per the WHO, IHD is one of the top ten causes of mortality worldwide. Moreover, the high prevalence of chronic conditions such as diabetes, hypertension, and cholesterol levels further increase the risk of suffering from cardiovascular diseases. An increase in the funding for the development of more advanced IHD drugs will help fuel the market growth. However, the availability of effective surgical treatments and catheter-based interventions may restrain the market growth.

The global ischemic heart disease drugs market is segmented on the basis of disease, drug class, and geography. Based on disease, the market is categorized into angina pectoris and myocardial infarction. Angina pectoris is further segmented into stable angina, unstable angina, and Prinzmetal's angina. Myocardial infarction is further bifurcated into STEMI and NSTEMI. Based on formulation type, the market is categorized into liposomes & nanoparticles, solution, emulsion, suspension, and ointment. Based on disease type, the market is further segmented into glaucoma, diabetic retinopathy, dry eye syndrome, macular degeneration, cataract, diabetic macular edema, and others. Based on end-users, the market is divided into hospitals, ophthalmic clinics, ambulatory surgical centers, and homecare settings. Based on geography, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as AstraZeneca, Actelion, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Baxter, Eli Lilly and Company, Novartis, Pfizer, and Sanofi have also been provided in this report.

Key Benefits

This report provides an extensive analysis of the current and emerging market trends and dynamics in the global market.
This report entails a detailed quantitative analysis of the current market and estimations from 2017-2023, which assists in identifying prevailing market opportunities.
The projections in this report are made by analyzing the current trends and future market potential from 2017 to 2023 in terms of value.
Competitive intelligence helps understand the competitive scenario globally
An in-depth analysis of current research and clinical developments within the market has been provided with key market dynamic factors that help understand the behavior of the market.

Ischemic Heart Disease Drugs Market Key Segments:

By Disease

Angina Pectoris
- Stable Angina
- Unstable Angina
- Prinzmetal's Angina
Myocardial Infarction
- STEMI
- NSTEMI

By Drug Class

Anti-dyslipidemic Drugs
Calcium Channel Blockers
Beta-blockers
ACE Inhibitors
ARBs
Vasodilators
Antithrombotic Agents

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Taiwan
- Rest of Asia-Pacific
LAMEA
- Brazil
- Turkey
- Saudi Arabia
- South Africa
- Rest of LAMEA

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

License Type

Data Pack

Single User PDF

Five User Online/PDF

Enterprise Online/PDF

LICENSE INFO

Users/Sharing

Restricted to one authorized user

Limited to 5 authorized users

Unlimited within company / enterprise

Printing

One Print only

Up to Five Copies

Unlimited within company / enterprise

Delivery Formats

ADDED BENIFITS

20% Free customization (Pre-sale)

16 Analyst hour support (Post Sale)

40 Analyst hour support (Post Sale)

160 hours of mini-consult

Free quarterly industry update

Free report on update (within 180 days)

MULTIPLE PURCHASE

Complimentary report with 2 reports

Complimentary report with 3 reports

Subscription Model

Have questions ?
Speak with analyst

Did you miss anything?
To add more

* Taxes/Fees, If applicable, will be
added at the checkout. All prices in USD.

Need More Information

+1-503-894-6022

help@alliedmarketresearch.com

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to eliminate redundant information to provide valued information and save time of the reader

Get fresh content delivered

Get insights on topics that matter to your business. Stay updated on the areas that interest you.

Report Title: Ischemic Heart Disease Drugs Market by Disease (Angina Pectoris [Stable Angina, Unstable Angina, and Prinzmetals Angina], and Myocardial Infarction [STEMI and NSTEMI]) and by Drug Class (Anti-dyslipidemic Drugs, Calcium Channel Blockers, Beta-blockers, ACE Inhibitors, ARBs, Vasodilators, and Antithrombotic Agents) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Select Chapters

Chapter 1 Chapter 2 Chapter 3 Chapter 4 Chapter 5 Chapter 6 Chapter 7

Full Name: *:

Company Name: *:

Job Role: *:

Email: *:

Country: *:

Contact Number: *:

How can we help? *:

Security Code: *:

STAY WITH US

WE ACCEPT

* Pricing on the website is provided for single users licenses only. All reports will be provided in a PDF format for download. To purchase multi-user licenses, please contact us at +1-800-792-5285 or send an email to sales@alliedmarketresearch.com
Chapter: 1 INTRODUCTION 1.1. REPORT DESCRIPTION 1.2. KEY BENEFITS 1.3. KEY MARKET SEGMENTS 1.4. RESEARCH METHODOLOGY 1.4.1. Secondary research 1.4.2. Primary research 1.4.3. Analyst tools & models
Chapter: 2 EXECUTIVE SUMMARY 2.1. CXO PERSPECTIVE
Chapter: 3 MARKET OVERVIEW 3.1. MARKET DEFINITION AND SCOPE 3.2. KEY FINDINGS 3.2.1. Top investment pockets 3.2.2. Top winning strategies 3.3. MARKET SHARE ANALYSIS, 2016 3.4. PORTER’S FIVE FORCES ANALYSIS 3.4.1. MARKET DYNAMICS 3.4.2. Drivers 3.4.3. Restraints 3.4.4. Opportunities
Chapter: 4 ISCHEMIC HEART DISEASE DRUGS MARKET, BY DISEASE 4.1. OVERVIEW 4.1.1. Market size and forecast 4.2. ANGINA PECTORIS 4.2.1. Key market trends 4.2.2. Growth factors and opportunities 4.2.3. Market size and forecast 4.2.4. Stable Angina 4.2.5. Unstable Angina 4.2.6. Prinzmetal's Angina 4.3. MYOCARDIAL INFARCTION 4.3.1. Key market trends 4.3.2. Growth factors and opportunities 4.3.3. Market size and forecast 4.3.4. STEMI 4.3.5. NSTEMI
Chapter: 5 ISCHEMIC HEART DISEASE DRUGS MARKET, BY DRUG CLASS 5.1. OVERVIEW 5.1.1. Market size and forecast 5.2. ANTI-DYSLIPIDEMIC DRUGS 5.2.1. Market size and forecast 5.3. CALCIUM CHANNEL BLOCKERS 5.3.1. Market size and forecast 5.4. BETA-BLOCKERS 5.4.1. Market size and forecast 5.5. ACE INHIBITORS 5.5.1. Market size and forecast 5.6. ARBS 5.6.1. Market size and forecast 5.7. VASODILATORS 5.7.1. Market size and forecast 5.8. ANTITHROMBOTIC AGENTS 5.8.1. Market size and forecast
Chapter: 6 ISCHEMIC HEART DISEASE DRUGS MARKET, BY GEOGRAPHY 6.1. OVERVIEW 6.2. NORTH AMERICA 6.2.1. Key market trends 6.2.2. Key growth factors and opportunities 6.2.3. Market size and forecast 6.2.3.1. U.S. market size and forecast 6.2.3.2. Canada market size and forecast 6.2.3.3. Mexico market size and forecast 6.2.4. North America Ischemic Heart Disease Drugs Market by Disease 6.2.5. North America Ischemic Heart Disease Drugs Market by Drug Class 6.3. EUROPE 6.3.1. Key market trends 6.3.2. Key growth factors and opportunities 6.3.3. Market size and forecast 6.3.3.1. Germany market size and forecast 6.3.3.2. France market size and forecast 6.3.3.3. UK market size and forecast 6.3.3.4. Italy market size and forecast 6.3.3.5. Spain market size and forecast 6.3.3.6. Rest of Europe market size and forecast 6.3.4. Europe Ischemic Heart Disease Drugs Market by Disease 6.3.5. Europe Ischemic Heart Disease Drugs Market by Drug Class 6.4. ASIA-PACIFIC 6.4.1. Key market trends 6.4.2. Key growth factors and opportunities 6.4.3. Market size and forecast 6.4.3.1. Japan market size and forecast 6.4.3.2. China market size and forecast 6.4.3.3. Australia market size and forecast 6.4.3.4. India market size and forecast 6.4.3.5. South Korea market size and forecast 6.4.3.6. Taiwan market size and forecast 6.4.3.7. Rest of Asia-Pacific market size and forecast 6.4.4. Asia-Pacific Ischemic Heart Disease Drugs Market by Disease 6.4.5. Asia-Pacific Ischemic Heart Disease Drugs Market by Drug Class 6.5. LAMEA 6.5.1. Key market trends 6.5.2. Key growth factors and opportunities 6.5.3. Market size and forecast 6.5.3.1. Brazil market size and forecast 6.5.3.2. Turkey market size and forecast 6.5.3.3. Saudi Arabia market size and forecast 6.5.3.4. South Africa market size and forecast 6.5.3.5. Rest of LAMEA market size and forecast 6.5.4. LAMEA Ischemic Heart Disease Drugs Market by Disease 6.5.5. LAMEA Ischemic Heart Disease Drugs Market by Drug Class
Chapter: 7 COMPANY PROFILES 7.1. ASTRAZENECA 7.1.1. Operating business segments 7.1.2. Business performance 7.1.3. Key strategic moves and developments 7.2. ACTELION 7.2.1. Operating business segments 7.2.2. Business performance 7.2.3. Key strategic moves and developments 7.3. BAYER 7.3.1. Operating business segments 7.3.2. Business performance 7.3.3. Key strategic moves and developments 7.4. BOEHRINGER INGELHEIM 7.4.1. Operating business segments 7.4.2. Business performance 7.4.3. Key strategic moves and developments 7.5. BRISTOL-MYERS SQUIBB 7.5.1. Operating business segments 7.5.2. Business performance 7.5.3. Key strategic moves and developments 7.6. BAXTER 7.6.1. Operating business segments 7.6.2. Business performance 7.6.3. Key strategic moves and developments 7.7. ELI LILLY AND COMPANY 7.7.1. Operating business segments 7.7.2. Business performance 7.7.3. Key strategic moves and developments 7.8. NOVARTIS 7.8.1. Operating business segments 7.8.2. Business performance 7.8.3. Key strategic moves and developments 7.9. PFIZER 7.9.1. Operating business segments 7.9.2. Business performance 7.9.3. Key strategic moves and developments 7.10. SANOFI 7.10.1. Operating business segments 7.10.2. Business performance 7.10.3. Key strategic moves and developments

Purchase Options